U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
Go back to U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer| (NASDAQ: RVMD) | Delayed: 190.95 -5.99 (3.04%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $196.94 | 52 Week High | $ | |||
| Open | $197.00 | 52 Week Low | $ | |||
| Day High | $197.10 | P/E | N/A | |||
| Day Low | $188.18 | EPS | $ | |||
| Volume | 5,939,946 | |||||
